157 related articles for article (PubMed ID: 25549213)
21. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2.
Tsubaki M; Satou T; Itoh T; Imano M; Yanae M; Kato C; Takagoshi R; Komai M; Nishida S
Mol Cell Endocrinol; 2012 Sep; 361(1-2):219-31. PubMed ID: 22579611
[TBL] [Abstract][Full Text] [Related]
23. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
24. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
25. Compressive force induces osteoclast differentiation via prostaglandin E(2) production in MC3T3-E1 cells.
Sanuki R; Shionome C; Kuwabara A; Mitsui N; Koyama Y; Suzuki N; Zhang F; Shimizu N; Maeno M
Connect Tissue Res; 2010 Apr; 51(2):150-8. PubMed ID: 20001844
[TBL] [Abstract][Full Text] [Related]
26. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
27. Dual modulation of osteoclast differentiation by lipopolysaccharide.
Zou W; Bar-Shavit Z
J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
[TBL] [Abstract][Full Text] [Related]
28. The effect of P2X7R- mediated Ca
Ma Y; Ran D; Zhao H; Shi X; Song R; Zou H; Liu Z
Life Sci; 2022 Mar; 293():120337. PubMed ID: 35074408
[TBL] [Abstract][Full Text] [Related]
29. The effect of P2X7R-mediated Ca
Ma Y; Zhao H; Chile C; Wang C; Zheng J; Song R; Zou H; Gu J; YanYuan ; Bian J; Liu Z
Exp Cell Res; 2019 Oct; 383(2):111555. PubMed ID: 31415763
[TBL] [Abstract][Full Text] [Related]
30. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
31. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Lacey DL; Tan HL; Lu J; Kaufman S; Van G; Qiu W; Rattan A; Scully S; Fletcher F; Juan T; Kelley M; Burgess TL; Boyle WJ; Polverino AJ
Am J Pathol; 2000 Aug; 157(2):435-48. PubMed ID: 10934148
[TBL] [Abstract][Full Text] [Related]
32. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
33. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro.
Al-Dujaili SA; Lau E; Al-Dujaili H; Tsang K; Guenther A; You L
J Cell Biochem; 2011 Sep; 112(9):2412-23. PubMed ID: 21538477
[TBL] [Abstract][Full Text] [Related]
34. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.
Grcević D; Lukić IK; Kovacić N; Ivcević S; Katavić V; Marusić A
Clin Exp Immunol; 2006 Oct; 146(1):146-58. PubMed ID: 16968409
[TBL] [Abstract][Full Text] [Related]
35. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
36. High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor.
Chen T; Knapp AC; Wu Y; Huang J; Lynch JS; Dickson JK; Lawrence RM; Feyen JH; Agler ML
Assay Drug Dev Technol; 2006 Aug; 4(4):387-96. PubMed ID: 16945012
[TBL] [Abstract][Full Text] [Related]
37. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
[TBL] [Abstract][Full Text] [Related]
38. Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation.
Park K; Ju WC; Yeo JH; Kim JY; Seo HS; Uchida Y; Cho Y
Int J Mol Med; 2014 Jan; 33(1):178-84. PubMed ID: 24248634
[TBL] [Abstract][Full Text] [Related]
39. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
Sugatani T; Alvarez UM; Hruska KA
J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
[TBL] [Abstract][Full Text] [Related]
40. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
Aoyama E; Kubota S; Khattab HM; Nishida T; Takigawa M
Bone; 2015 Apr; 73():242-8. PubMed ID: 25554597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]